Back to top
more

Cyclacel Pharmaceuticals (CYCC)

(Delayed Data from NSDQ)

$1.85 USD

1.85
37,911

-0.11 (-5.61%)

Updated Apr 18, 2024 03:59 PM ET

After-Market: $1.85 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Buy Stocks for October 17th

by Zacks Equity Research

MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.

Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Cyclacel Pharmaceuticals, Inc. (CYCC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.

Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release

by Zacks Equity Research

Wix's (WIX) Q3 performance is likely to have benefited from strong bookings growth and an improvement in the user base. Forex volatility and weakness in global macroeconomic conditions are likely to have acted as headwinds.

    Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.

    Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.

    Company News for Apr 21, 2020

    by Zacks Equity Research

    Companies In The News Are: CYCC, CODX, NBY, EXEL

    Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

    Company News for April 11, 2017

    by Zacks Equity Research

    Companies in the News are: SWFT,KNX,WFM,STRP,T,CYCC